Johnson Pharmacare Reports Wider Net Loss in Q1 FY2026, Expenses Rise Jul 23, 2025
Johnson & Johnson's Talc Claims Bankruptcy Plan Rejected for Third Time Apr 01, 2025
More news about Johnson Pharmacare
12Mar 25
Johnson & Johnson Secures ₹3.34 Crore Victory in Delhi High Court Counterfeit Case
Johnson & Johnson has won a significant legal battle against counterfeit medical products in India. The Delhi High Court awarded J&J ₹3.34 crore in damages and issued a permanent injunction against the defendants for manufacturing and selling fake surgical products under J&J's trademarks. The court emphasized the public health risks posed by counterfeit medical products. This ruling reinforces J&J's brand protection efforts, commitment to patient safety, and sends a strong message to counterfeiters in the healthcare industry.
19Feb 25
Johnson & Johnson Faces Crucial Moment in $9 Billion Baby Powder Settlement
Johnson & Johnson is seeking approval for a $9 billion settlement to resolve lawsuits claiming its baby powder caused cancer. A lawyer representing 20,000 women is urging the court to approve the settlement. J&J's use of Chapter 11 bankruptcy strategy has faced opposition, including from the U.S. Trustee. The pre-bankruptcy voting process has also been questioned. If approved, this would be one of the largest mass tort litigation settlements in U.S. history, potentially allowing J&J to move past the controversy.